Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01267279
Recruitment Status : Completed
First Posted : December 28, 2010
Last Update Posted : January 26, 2015
Information provided by (Responsible Party):
David F. Scott, MD, Spokane Joint Replacement Center

Brief Summary:
In a randomized, double-blind trial, BMD of the operated proximal femur after total hip replacement measured by dual-energy x-ray absorptiometry (DXA) were compared for up to two years in patients receiving IV ZOL 5 mg infusion (n = 27) or placebo (IV saline infusion; n = 24) at two weeks and one year after surgery.

Condition or disease Intervention/treatment Phase
Osteoporosis Drug: Zoledronic acid Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 66 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty
Study Start Date : January 2005
Actual Primary Completion Date : December 2014
Actual Study Completion Date : December 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: Placebo group Drug: Zoledronic acid
Zoledronic acid per protocol
Other Name: Reclast

Experimental: Study drug group Drug: Zoledronic acid
Zoledronic acid per protocol
Other Name: Reclast

Primary Outcome Measures :
  1. Bone mineral density [ Time Frame: 5 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Patients undergoing primary elective total hip replacement

Exclusion Criteria:

  • Osteoporosis (BMD ≤-2.5)
  • Trauma to the operated femur, hip revisions, femoral dysplasia, trochanteric osteotomy, inflammatory arthritis
  • Severe renal impairment
  • Use of any medications affecting BMD
  • Known sensitivity to bisphosphonates
  • Severe dental problems, and pregnancy or being able to conceive and not using reliable birth control methods

Responsible Party: David F. Scott, MD, PI, Spokane Joint Replacement Center Identifier: NCT01267279     History of Changes
Other Study ID Numbers: SJRC-Reclast
First Posted: December 28, 2010    Key Record Dates
Last Update Posted: January 26, 2015
Last Verified: January 2015

Additional relevant MeSH terms:
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Zoledronic acid
Bone Density Conservation Agents
Physiological Effects of Drugs